Every material Form 8-K Alnylam Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alnylam's board authorized a program to repurchase up to $1.0 billion of its common stock on November 2, 2026. The company also said Executive Vice President and Chief Commercialization Officer Tolga Tanguler will leave in December 2026, with a separation agreement still to be signed.
Board authorized a repurchase program of up to $1.0 billion of common stock on November 2, 2026.
The company anticipates repurchasing about $500 million by the end of 2026 and the balance during 2027.
The program has no expiration date and does not obligate the company to buy any particular amount; it may be modified, suspended or discontinued at any time.
Tolga Tanguler, Executive Vice President and Chief Commercialization Officer, will depart in December 2026; the terms of his departure are yet to be set in a written agreement.
Alnylam reported third quarter 2026 total revenues of $1.46 billion, up 17% from a year earlier, led by net product revenues of $1.29 billion, up 52%. GAAP net income reached $2.17 billion, or $15.72 per diluted share, but that figure includes a $1.9 billion income tax benefit, while GAAP income from operations fell 6% to $345.8 million. The company reiterated its full-year 2026 guidance.
Total revenues were $1,458.1 million versus $1,249.0 million in Q3 2025, up 17%.
Total net product revenues were $1,292 million, up 52%, with Total TTR net product revenues at $1,150 million.
GAAP income from operations was $345.8 million, down 6% from $368.0 million, while GAAP diluted EPS was $15.72 versus $2.14, helped by a $1.9 billion tax benefit.
Full-year 2026 total net product revenues guidance of $4,700 million to $5,100 million was reiterated.
Alnylam reported second-quarter 2026 total revenues of $1.29 billion, up 67% from a year earlier, and GAAP net income of $164 million, compared with a net loss of $72 million in the prior-year quarter. The company lowered its full-year 2026 TTR net product revenue guidance to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, citing normalizing second-line demand for AMVUTTRA in the U.S.
Q2 2026 total revenues were $1,290.9 million, up 67% from $773.7 million in Q2 2025.
GAAP net income was $164.5 million, or $1.21 per diluted share, versus a loss of $0.55 per share a year earlier.
Full-year 2026 TTR net product revenue guidance was cut to $4,200 million to $4,500 million from $4,400 million to $4,700 million.
Full-year 2026 collaboration and royalty revenue guidance was raised to $575 million to $625 million from $400 million to $500 million.
Effective June 1, 2026, Alnylam expanded its board from ten to eleven members and elected Benjamin F. Cravatt, Ph.D. to fill the new seat. At its annual meeting, stockholders re-elected three Class I directors and approved executive pay in a non-binding vote, though one director's support was notably lower than the others.
Dr. Cravatt receives a $75,000 annual cash retainer and a stock option with a $600,000 grant date fair value.
Stuart A. Arbuckle, Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D. were re-elected as Class I directors to serve until the 2029 annual meeting.
Stockholders approved executive compensation with 111,772,389 votes for and 8,552,534 against.
PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 119,847,735 votes for.
Alnylam reported first-quarter 2026 total revenues of $1.17 billion, up 96% from $594 million a year earlier, with AMVUTTRA driving most of the growth. GAAP net income was $206 million, or $1.51 per diluted share, compared with a net loss of $18 million a year earlier. The company reiterated, rather than changed, its full-year 2026 guidance for total net product revenues of $4.9 billion to $5.3 billion.
Total revenues of $1.17 billion in Q1 2026, up 96% from $594 million in Q1 2025.
GAAP net income of $206 million, or $1.51 per diluted share, versus a net loss of $18 million, or $0.14 per share, a year earlier.
Total net product revenues of $1.04 billion, up 121%; AMVUTTRA contributed $890 million.
Full-year 2026 total net product revenues guidance of $4.9 billion to $5.3 billion was reiterated.
Alnylam's Board granted CEO Yvonne Greenstreet a special performance share award effective March 2, 2026, with a target of 55,373 shares and a stated face value of $18.0 million. The award pays out only if the stock's future 30-day average price reaches thresholds starting at $500 and reaching $800 by December 31, 2029, so it creates no value unless shareholders see significant stock price gains.
Target award: 55,373 performance share units, face value $18.0 million based on the $325.07 closing price on the Grant Date
Vesting range: 50% to 200% of target, tied to future average stock price thresholds of $500, $600, $700 and $800
Baseline threshold of $500 must be met or the award is forfeited in full; vesting date is December 31, 2029
The award was granted concurrently with the March 2, 2026 annual equity grants to Greenstreet and other executives
Alnylam reported fourth quarter 2025 total revenues of $1.1 billion, up 85% from a year earlier, and GAAP net income of $111.5 million, compared with a net loss of $83.8 million in the same quarter of 2024. For the full year, total revenues were $3.71 billion, up 65%, and GAAP net income was $313.7 million, compared with a net loss of $278.2 million in 2024. The company reiterated its 2026 total net product revenue guidance of $4.9 billion to $5.3 billion.
Q4 2025 total net product revenues were $995 million, up 121%, led by AMVUTTRA at $827 million.
Full-year 2025 GAAP net income was $313.7 million, versus a net loss of $278.2 million in 2024.
2026 total net product revenue guidance of $4,900 million to $5,300 million was reiterated.
Cash, cash equivalents and marketable securities were $2.91 billion as of December 31, 2025.
Alnylam announced preliminary 2025 global net product revenues of approximately $2,987 million, up 81% from 2024, and full year 2026 combined net product revenue guidance of $4,900 million to $5,300 million. The company also launched a five-year strategy called Alnylam 2030. The figures are unaudited and subject to adjustment until complete results are released in February 2026.
Preliminary fourth quarter 2025 net product revenues were approximately $995 million; full year 2025 was approximately $2,987 million.
2026 combined net product revenue guidance is $4,900 million to $5,300 million, including Total TTR guidance of $4,400 million to $4,700 million.
Results are preliminary and unaudited; complete fourth quarter and full year 2025 results are expected in February 2026.
Management will discuss the results and guidance in a webcast on January 12, 2026 at 9:00 am PT.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alnylam Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →